NICE approves reslizumab for severe eosinophilic asthma

NICE has approved the use of reslizumab (Cinqaero) as an add-on therapy for the treatment of inadequately controlled severe eosinophilic asthma.

by Sandhiya Sodha
Treatment options for people with severe asthma are limited. | STEVE GSCHMEISSNER/SCIENCE PHOTO LIBRARY
Treatment options for people with severe asthma are limited. | STEVE GSCHMEISSNER/SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package